Nuvo Pharmaceuticals Inc NRIFF

Circassia suggests WF10 worth $1 billion

[paljoey]

• Latest entrant is Circassia, a U.K. based company developing

  immunotherapy for allergies

  • Branded SPIRE = “synthetic peptide immune-regulatory epitopes”

  • Each SPIRE therapy targets a specific allergen (i.e. cat or ragweed or

    grass)

• SPIRE drugs and WF10 appear to have similarities

  • Administered by series of needles (Circassia) or infusions (WF10)

  • Long-term treatment effect for about 2 years after short course of

    treatment

• But SPIRE treatments are allergen specific whereas WF10 treats all airborne allergens

• Circassia recently raised $333M in an IPO in London resulting in a $1B market cap